ArticleCancers2022
Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 7 citations in OpenAlex.
- Web-based application of integrated clinico-genomic prognostic nomograms in metastatic castration-resistant prostate cancer.The journal of liquid biopsy · 2026Article
- Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC).The journal of liquid biopsy · 2026Article
- Prognostic value of circulating tumor DNA and copy-number alterations in patients receiving tandem [BMC cancer · 2026Observational
- Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer.JNCI cancer spectrum · 2026Article
- Plasma cell-free DNA methylation-based prognosis in metastatic castrate-resistant prostate cancer.NPJ precision oncology · 2025Article
- Omics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology.International journal of molecular sciences · 2025Review
- Multi-gene risk score for prediction of clinical outcomes in treatment-naïve metastatic castrate-resistant prostate cancer.JNCI cancer spectrum · 2025Article
- Multigene Copy Number Alteration Risk Score Biomarker-Based Enrichment Study Designs in Metastatic Castrate-Resistant Prostate Cancer.JCO precision oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
Prostate cancer (PCa) accounted for more than 34,000 deaths in US males [...].
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.